J. Graff

S. Baylin, S. Kuerbitz, J. Graff, 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Deletion of p 16 INK 4 A / CDKN 2 and p 15 INK 4 B in Human Somatic Cell Hybrids and Hybrid-derived Tumors 1

S. Baylin, S. Kuerbitz, J. Graff, 1998 .

Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression.

S. Baylin, G. Yancopoulos, K. Romans, 1999, Proceedings of the National Academy of Sciences of the United States of America.

E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.

J. Herman, S. Baylin, W. Isaacs, 1995, Cancer research.

Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression*

J. Herman, S. Baylin, E. Gabrielson, 2000, The Journal of Biological Chemistry.

Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Liang Cheng, George J Eckert, Liang Cheng, 2002, The American journal of pathology.

Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs

S. Zimmer, J. Graff, 2004, Clinical & Experimental Metastasis.

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.

E. Legius, O. Maertens, J. Graff, 2016, The Journal of clinical investigation.

Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.

J. Herman, S. Baylin, W. Westra, 1998, Cancer research.

Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis

J. Deddens, J. Graff, M. Marshall, 2004, Clinical Cancer Research.

Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

J. Herman, S. Baylin, J. Costello, 1999, Cancer research.

Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression*

R. Vessella, G. Sandusky, J. Graff, 2000, The Journal of Biological Chemistry.

Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma

J. Deddens, J. Graff, J. H. Carter, 2016, British Journal of Cancer.

Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

N. Sonenberg, J. Pelletier, D. Ruggero, 2015, Cancer research.

Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide

R. Kratzke, J. Graff, B. Jacobson, 2013, PloS one.

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

J. Deddens, J. Graff, J. H. Carter, 2009, Cancer research.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Tao Wang, Hong Zhang, N. Dean, 2007, The Journal of clinical investigation.

Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis

Nahum Sonenberg, N. Sonenberg, J. Graff, 2010, Molecular Cancer Therapeutics.

Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.

S. Zimmer, J. Graff, A. DeBenedetti, 2000, Anticancer research.

Int7G24A Variant of Transforming Growth Factor-β Receptor Type I Is Associated with Invasive Breast Cancer

J. Deddens, J. Graff, M. Markey, 2006, Clinical Cancer Research.

Abstract C201: The combination of the small molecule TGFβR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth.

J. Graff, J. Yingling, R. Foreman, 2011 .

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

R. Campbell, P. Iversen, J. Graff, 2005 .

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

J. Graff, M. Uhlik, N. Bose, 2022, Frontiers in Oncology.

Small Molecule Therapeutics Characterization of LY 2228820 Dimesylate , a Potent and Selective Inhibitor of p 38 MAPK with Antitumor Activity

R. Campbell, J. Velasco, J. Graff, 2014 .

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

R. Campbell, J. Velasco, J. Graff, 2011, Molecular Cancer Therapeutics.

Characterization of LY 2228820 dimesylate , a potent and selective inhibitor of p 38 MAPK with anti-tumor activity

R. Campbell, J. Velasco, J. Graff, 2013 .

The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.

David C. Jones, J. Graff, B. Neubauer, 2003, Cancer research.

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

J. Graff, R. Walgren, C. Shih, 2012, Investigational New Drugs.

Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.

J. Deddens, J. Graff, J. H. Carter, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hypomethylation of pericentromeric DNA in breast adenocarcinomas

S. Baylin, M. Ehrlich, W. Ji, 1998, International journal of cancer.

Int 7 G 24 A Variant of Transforming Growth Factor-B Receptor Type I Is Associatedwith Invasive Breast Cancer

J. Deddens, J. Graff, M. Markey, 2006 .

The Emerging Role for the mRNA Cap-Binding Protein, EIF-4E, in Metastatic Progression

S. Zimmer, J. Graff, 2002 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.

P. Iversen, L. Platanias, J. Graff, 2013, Blood.

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

J. Graff, N. Bose, A. Chan, 2016, PloS one.

In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography

G. Hutchins, K. Pollok, J. Graff, 2009, Journal of oncology.

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

J. Graff, M. Uhlik, Kathryn A. Fraser, 2019, The Journal of Immunology.

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

J. Graff, M. Uhlik, B. Osterwalder, 2018, Immunology.

Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

J. Graff, Kathryn A. Fraser, N. Bose, 2016 .

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

Christos G. Gkogkas, K. Nader, J. Lacaille, 2014, Cell reports.

An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder

J. Deddens, J. Graff, J. H. Carter, 2004, International journal of cancer.

The Progression of LNCaP Human Prostate Cancer Cells to Androgen Independence Involves Decreased FOXO3a Expression and Reduced p27KIP1 Promoter Transactivation

J. Graff, B. Neubauer, B. Konicek, 2005, Molecular Cancer Research.

Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer

Eric W. Su, David G. Beer, George E. Sandusky, 2004 .

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

A. Stopeck, V. Borges, J. Graff, 2020 .

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

J. Graff, N. Bose, A. Chan, 2015 .

913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab

H. Hirsch, J. Graff, S. Fiset, 2022, Regular and Young Investigator Award Abstracts.

Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas.

J. Graff, J. H. Carter, J. Triplett, 2001, Cancer research.

Mechanisms of inactivation of E-cadherin in breast cancer cell lines.

D Pinkel, T. Godfrey, D. Pinkel, 1998, Cancer research.

Abstract B019: Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production

J. Graff, Michael E. Danielson, Kyle S. Michel, 2016 .

Abstract A015: Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages

J. Graff, N. Bose, A. Chan, 2016 .

Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity

J. Graff, A. Chan, Lindsay R. Wurst, 2016 .

Kidney , Brain , and Other Human Cancers Gene Suggests a Suppressor Role in Metalloproteinase-3 Methylation-associated Silencing of the Tissue Inhibitor of Updated Version

J. Herman, S. Baylin, J. Costello, 1999 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

N. Sonenberg, J. Pelletier, P. Iversen, 2011, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype

J. Graff, Xiahong Qiu, Kathryn A. Fraser, 2015, Journal of Immunotherapy for Cancer.